福元医药(601089.SH)：获得化学原料药上市申请批准通知书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received approval from the National Medical Products Administration for the raw material drug Clobetasol, which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 2 and above [1] Group 1 - The approval of Clobetasol will enrich the company's product line [1] - This development is expected to promote the company's sustainable, stable, and healthy growth [1]